LAUSR

The introduction of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) agents has lead to paradigm shifts in management of retinal disorders of various etiologies. We have come a long way from macular photocoagulation for neovascular age‐related macular degeneration (nAMD) and grid laser photocoagulation for macular edema secondary to vein occlusions (RVO) and diabetic retinopathy (DME). The fact that intravitreal injections have become mainstay in the treatment of these diseases is common knowledge now and most ophthalmologists do not hesitate in initiating treatment. Yet there appears hesitancy in advising reinjections. In this editorial, I discuss important aspects of treatment regimens and various different drugs available to us, with special emphasis on biosimilars and newer agents that have the potential to revolutionize treatments and reduce treatment burden.